Curis Commences ~$8.5M Offering Of 16.666M Common Shares, Warrants At $0.51 Per Share
Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
Curis is selling new shares to raise about 8.5 million dollars. When a company does this, it means existing owners get a smaller piece, but the company gets cash to keep working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.